NR1H4 and metabolic dysfunction-associated steatohepatitis: BA receptor farnesoid X receptor (FXR) is a promising drug target for NASH, and FXR agonists are currently tested in clinical trials for NASH (Gonzalez et al., 2016; Schmidt et al., 2017).